April 2020 Clinical Watch Newsletter

May 21, 2020

In this issue of Clinical Watch, we highlight the NIH Panel recommendations regarding medications associated with COVID-19 treatment and suggest prior authorization criteria for the first approved treatment for erythropoietic protoporphyria. Lastly, we review claims data to identify potential users for a new treatment for heavy menstrual bleeding associated with uterine fibroids.

For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.

Previous Article
Webinar: Midas COVID-19 Resources – Rapid Optimization of Current Investments
Webinar: Midas COVID-19 Resources – Rapid Optimization of Current Investments

Next Flipbook
March 2020 Clinical Watch Newsletter
March 2020 Clinical Watch Newsletter

In this issue of Clinical Watch, we highlight aspects of Medicaid programs that are affected COVID-19 and s...